The World Health Organization has released new guidelines on the use of GLP-1 drugs, such as Ozempic, Wegovy, Mounjaro, and Zepbound, to tackle the global obesity crisis. These medications have gained popularity, with an estimated 1 in 8 American adults having tried them, according to a 2024 poll.
The WHO's guidelines offer two key recommendations. Firstly, GLP-1 drugs can be prescribed to adults with obesity, excluding pregnant women, due to limited long-term data. The organization emphasizes the need for further research on the effects of discontinuing these medications and the potential financial burden of long-term use.
Secondly, the WHO stresses that GLP-1 drugs are not a panacea. They should be used in conjunction with other strategies, such as dietary and exercise modifications. Dr. Francesca Celletti, a WHO senior advisor, highlights that medication alone cannot solve obesity. This aligns with existing research, which underscores the importance of maintaining a balanced diet and engaging in regular physical activity while taking these drugs.
Moreover, the WHO acknowledges that obesity is a societal issue, requiring more than individual treatment. Dr. Karen Sealey, director of the Healthy Caribbean Coalition and the Inter-American Heart Foundation, emphasizes the need for preventive measures and a holistic approach to address the complex nature of obesity.
As the debate surrounding GLP-1 drugs continues, it is crucial to consider their role within a comprehensive strategy for obesity management, while also addressing the underlying societal factors contributing to the issue.
